• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by TC BioPharm (Holdings) plc

    4/27/22 3:53:39 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCBP alert in real time by email
    SC 13D 1 ea158951-sc13drenais_tcbio.htm SCHEDULE 13D

     

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a)

     

    TC BioPharm (Holdings) plc
    (Name of Issuer)

     

    ADSs / Ordinary Shares
    (Title of Class of Securities)

     

    87807D 103

    (ISIN or CUSIP Number)

     

    Thomas Nicholls

    Renaissance Capital Partners Limited

    42 Shad Thames

    London SE1 2YD

    United Kingdom

     

    with a copy to:

     

    John P. Crutcher, Esq.

    Barton LLP,

    711 Third Avenue, 14th Floor

    New York, New York 10017

    (212-885-8858)

    (Name, Address and Telephone Number of Persons Authorized
    to Receive Notices and Communications)

     

    February 10, 2021
    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO.: 87807D 103

     

    1)

    NAME OF REPORTING PERSON

     

    Renaissance Capital Partners Limited

    2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☒

    (b) ☐

    3)

    SEC Use Only

     

     

    4)

    SOURCE OF FUNDS

     

    WC, OO1

    5)

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ☐

    6)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7) SOLE VOTING POWER

    8,468,1822
    8) SHARED VOTING POWER

    -0-
    9) SOLE DISPOSITIVE POWER

    8,648,1822
    10) SHARED DISPOSITIVE POWER

    -0-

    11)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,648,1822

    12)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)


    26%

    14)

    TYPE OF REPORTING PERSON

     

    CO

     

     

    1671,930 Ordinary Shares were held by the Renaissance Capital Partners prior to the IPO of the Issuer; 2,064,997 Ordinary Shares, and warrants for the purchase of 4,129,994 Ordinary Shares, were obtained upon the conversion of convertible notes held by Renaissance Capital Partners Limited. 16,556 Ordinary Shares were issued pursuant to contractual anti-dilution provisions between Renaissance Capital Partners and the Issuer.

     

    2Includes (a) Ordinary Shares and (b) warrants to purchase 5,306,464 Ordinary Shares, which warrants are or will be immediately exercisable within 60 days of the date of this Schedule.

     

    2

     

     

    CUSIP NO.: 87807D 103

     

    1)

    NAME OF REPORTING PERSON

     

    Kenneth Edward Randall

    2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☒

    (b) ☐

    3)

    SEC Use Only

     

     

    4)

    SOURCE OF FUNDS

     

    OO3

    5)

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ☐

    6)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7) SOLE VOTING POWER

    79,615
    8) SHARED VOTING POWER

    8,648,1824

    9) SOLE DISPOSITIVE POWER

    79,615
    10) SHARED DISPOSITIVE POWER

    8,648,1824

    11)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,727,1974

    12)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)


    26%

    14)

    TYPE OF REPORTING PERSON

     

    IN

     

     

    346,510 Ordinary Shares were held by Mr. Randall prior to the Initial Public Offering of the Issuer; 33,105 Ordinary Shares were issued pursuant to contractual anti-dilution provisions between Kenneth Edward Randall and the Issuer.

     

    4Includes (a) Ordinary Shares and (b) warrants to purchase 5,306,464 Ordinary Shares, which warrants are or will be immediately exercisable within 60 days of the date of this Schedule.

     

    3

     

     

    CUSIP NO.: 87807D 103

     

    1)

    NAME OF REPORTING PERSON

     

    Mark Edward Randall

    2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☒

    (b) ☐

    3)

    SEC Use Only

     

     

    4)

    SOURCE OF FUNDS

     

    OO5

    5)

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ☐

    6)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7) SOLE VOTING POWER

    497,615
    8) SHARED VOTING POWER

    8,648,1826

    9) SOLE DISPOSITIVE POWER

    497,615
    10) SHARED DISPOSITIVE POWER

    8,648,1826

    11)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,145,7976

    12)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    27%

    14)

    TYPE OF REPORTING PERSON

     


    IN

     

     

    5290,700 Ordinary Shares were held by Mr. Randall prior to the IPO of the Issuer; 206,195 Ordinary Shares were issued pursuant to contractual anti-dilution provisions between Mark Edward Randall and the Issuer.

     

    6Includes (a) Ordinary Shares and (b) warrants to purchase 5,306,464 Ordinary Shares, which warrants are or will be immediately exercisable within 60 days of the date of this Schedule.

     

    4

     

     

    CUSIP NO.: 87807D 103

     

    1)

    NAME OF REPORTING PERSON

     

    Diana Elizabeth Randall

    2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☒

    (b) ☐

    3)

    SEC Use Only

     

     

    4)

    SOURCE OF FUNDS

     

     

    5)

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ☐

    6)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7) SOLE VOTING POWER

    -0-
    8) SHARED VOTING POWER

    8,648,1827

    9) SOLE DISPOSITIVE POWER

    -0-
    10) SHARED DISPOSITIVE POWER

    8,648,1827

    11)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,648,1827

    12)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    26%

    14)

    TYPE OF REPORTING PERSON

     


    IN

     

     

    7Includes (a) Ordinary Shares and (b) warrants to purchase 5,306,464 Ordinary Shares, which warrants are or will be immediately exercisable within 60 days of the date of this Schedule.

     

    5

     

     

    Item 1. Security and Issuer

     

    The class of equity securities to which this Schedule 13D (this “Schedule 13D”) relates are the ordinary shares, £0.01 par value and ADSs related thereto (together, the “Ordinary Shares”) of TC BioPharm (Holdings) plc, a company formed in Scotland, under the Companies Act 2006 of the United Kingdom (the “Issuer”). The principal executive office of the Issuer is Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR Scotland, United Kingdom.

     

    For trading purposes of the Ordinary Shares on The NASDAQ Stock Market in the United States, the Issuer entered into an agreement with Bank of New York Mellon, as depository, to permit holders of Ordinary Shares to convert their Ordinary Shares into American Depositary Shares. The current conversion rate is one for one.

     

    Item 2. Identity and Background.

     

    (a)This Schedule 13D is being filed by:

     

    i.Renaissance Capital Partners Limited (“RCP”);

     

    ii.Kenneth Edward Randall;

     

    iii.Mark Edward Randall; and

     

    iv.Diana Elizabeth Randall.

     

    (b)The addresses of the Reporting Persons are:

     

    i.Renaissance Capital Partners Limited, 42 Shad Thames, London, United Kingdom, SE1 2YD;

     

    ii.Kenneth Edward Randall, c/o Renaissance Capital Partners Limited, 42 Shad Thames, London, United Kingdom, SE1 2YD;

     

    iii.Mark Edward Randall, c/o Renaissance Capital Partners Limited, 42 Shad Thames, London, United Kingdom, SE1 2YD;

     

    iv.Diana Elizabeth Randall, c/o Renaissance Capital Partners Limited, 42 Shad Thames, London, United Kingdom, SE1 2YD.

     

    (c)The Reporting Persons principal occupations are:

     

    i.RCP is engaged in the management of private investments;

     

    ii.Kenneth Edwards Randall is a director of Renaissance Capital Partners Limited;

     

    iii.Mark Edwards Randall is a director of Renaissance Capital Partners Limited;

     

    iv.Diana Elizabeth Randall is the spouse of Kenneth Edward Randall and a shareholder of RCP.

     

    6

     

     

    (d)During the past five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)During the past five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction or as a result of such a proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)Each of the Reporting Persons is a citizen of (or is organized under the laws of) the United Kingdom.

     

    Item 3. Source and Amount of Funds and Other Consideration.

     

    (a)RCP held, prior to the initial public offering of the Issuer, 671,930 Ordinary Shares and convertible notes which, at the time of the initial public offering were converted into 2,064,997 Ordinary Shares and 4,129,994 warrants for the purchase of Ordinary Shares. Pursuant to the provisions of certain contracts with the Issuer, an additional 16,556 Ordinary Shares were issued to RCP upon the initial public offering. RCP purchased, with working capital, 588,235, Ordinary Shares.

     

    (b)Kenneth Edward Randall held, prior to the initial public offering of the Issuer, 46,510 Ordinary Shares. Pursuant to the provisions of certain contracts with the Issuer, an additional 33,105 Ordinary Shares were issued to Mr. Randall upon the initial public offering.

     

    (c)Mark Edward Randall held, prior to the initial public offering of the Issuer, 290,700 Ordinary Shares of the Issuer. Pursuant to the provisions of certain contracts with the Issuer, an additional 206,195 Ordinary Shares were issued to Mr. Randall upon the initial public offering.

     

    (d)Diana Elizabeth Randall has not acquired Ordinary Shares.

     

    Item 4.Purpose of Transaction

     

    In the case of each of the Reporting Persons, the securities were acquired for investment purposes. Each Reporting Person intends to review his investment in the Issuer on a continuing basis and will routinely monitor a wide variety of investment considerations, including, without limitation, current and anticipated future trading prices for the Ordinary Shares, the Issuer’s financial position, operations, assets, prospects, strategic direction and business and other developments affecting the Issuer. The Reporting Person may from time to time take such actions with respect to his investment in the Issuer as he deems appropriate, including, without limitation, (i) acquiring additional Ordinary Shares or disposing of some or all of his Ordinary Shares (or other securities of the Issuer to the extent available); (ii) changing his current intentions with respect to any or all matters referred to in this Item 4; and/or (iii) engaging in hedging, derivative or similar transactions with respect to any securities of the Issuer, subject to any lock up agreements or other similar forms of agreements. Any acquisition or disposition of the Issuer’s securities may be made by means of open-market purchases or dispositions, privately negotiated transactions, direct acquisitions from or dispositions to the Issuer and derivative transactions.

     

    7

     

     

    At the date of this Schedule 13D, except as set forth in this Schedule 13D, none of the Reporting Persons has any plans or proposals which would result in:

     

    (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

     

    (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

     

    (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

     

    (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or fill any existing vacancies on the board;

     

    (e) Any material change in the present capitalization or dividend policy of the Issuer;

     

    (f) Any other material change in the Issuer’s business or corporate structure;

     

    (g) Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

     

    (h) Causing a class of securities of the Issuer to be delisted from a United States national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

    (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1940; or

     

    (j) Any action similar to any of those actions enumerated above.

     

    Item 5. Interests in Securities of the Issuer

     

    (a)The Reporting Persons beneficial ownership is as follows (for purposes of percentage calculations, the total number of outstanding shares includes 28,058,398 shares as reported by the Issuer plus the exercise of 5,306,464 warrants held by RCP):

     

    i.RCP directly owns an aggregate of 8,648,182 Ordinary Shares (which aggregate treats RCP’s warrants as having been exercised), representing 26% of the Issuer’s Ordinary Shares.

     

    ii.Kenneth Edward Randall beneficially owns an aggregate of 8,727,197 Ordinary Shares, representing 26% of the Issuer’s Ordinary Shares, which aggregate is comprised of 79,615 shares held directly and a shared interest in the RCP ownership set forth above.

     

    iii.Mark Edward Randall beneficially owns an aggregate of 9,145,797 Ordinary Shares, representing 27% of the Issuer’s Ordinary Shares, which aggregate is comprised of 497,615 shares held directly and a shared interest in the RCP ownership set forth above.

     

    iv.Diana Elizabeth Randall beneficially owns an aggregate of 8,648,182 Ordinary Shares, representing 26% of the Issuer’s Ordinary Shares, which aggregate is comprised solely of Ms. Randall’s shared interest in the RCP ownership set forth above.

     

    8

     

     

    (b)The Reporting Persons have power to vote or to dispose of Ordinary Shares as follows:

     

    i.RCP has sole power to vote and to dispose of 8,648,182 Ordinary Shares (assuming exercise of 5,306,464 warrants); RCP has sole power to vote and dispose of 3,341,718 Ordinary Shares (assuming no exercise of warrants).

     

    ii.Kenneth Edward Randall has sole power to vote and to dispose of 79,615 Ordinary Shares; Additionally, Mr. Randall has shared power to vote and to dispose of 8,648,182 Ordinary Shares held by RCP (assuming exercise of warrants).

     

    iii.Mark Edward Randall has sole power to vote and to dispose of 497,615 Ordinary Shares; Additionally, Mr. Randall has shared power to vote and to dispose of 8,648,182 Ordinary Shares held by RCP (assuming exercise of warrants).

     

    iv.Diana Elizabeth Randall has sole power to vote and to dispose of -0- Ordinary Shares; Mrs. Randall has shared power to vote and to dispose of 8,648,182 Ordinary Shares

     

    (c)The following transactions relating to the Ordinary Shares have occurred within the past 60 days:

     

    i.RCP has executed the following transactions:

     

    1.Execution of anti-dilution provisions with the Issuer at the time of the initial public offering of the Issuer, resulting in the issuance of 16,556 Ordinary Shares;

     

    2.Exercise of conversion rights upon $8,538,628 in principal amount of outstanding convertible notes at the time of the initial public offering of the Issuer, resulting in the issuance of 2,064,997 Ordinary Shares and warrants for the purchase of 4,129,994 Ordinary Shares with an exercise price of $4.25 per share;

     

    3.Purchase, at the time of the initial public offering, for $2,500,000 in cash, of 588,235 Ordinary Shares and warrants for the purchase of Ordinary Shares with an exercise price of $4.25 per share.

     

    ii.Kenneth Edward Randall executed, at the time of the initial public offering of the Issuer, anti-dilution provisions with the Issuer, resulting in the issuance of 33,105 Ordinary Shares.

     

    iii.Mark Edward Randall executed, at the time of the initial public offering of the Issuer, anti-dilution provisions with the Issuer, resulting in the issuance of 206,195 Ordinary Shares.

     

    (d)Not applicable.

     

    (e)Not applicable.

     

    Item 6. CONTRACTS, ARRANGEMENTS UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

     

    Not applicable.

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS.

     

    Exhibit I:   Joint Filing Agreement

     

    9

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated as of: April 27, 2022

     

      Renaissance Capital Partners Limited
       
      /s/ Thomas Nicholls
      Thomas Nicholls
      Chief Financial Officer
       
      Kenneth Edward Randall
       
      /s/ Kenneth Edward Randall
      Kenneth Edward Randall
       
      Mark Edward Randall
       
      /s/ Mark Edward Randall
      Mark Edward Randall
       
      Diana Elizabeth Randall
       
      /s/ Diana Elizabeth Randall
      Diana Elizabeth Randall

     

     

    10

     

    Get the next $TCBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCBP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TCBP
    SEC Filings

    See more
    • SEC Form 6-K filed by TC BioPharm (Holdings) plc

      6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)

      3/21/25 11:22:27 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by TC BioPharm (Holdings) plc

      6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)

      2/10/25 4:05:27 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by TC BioPharm (Holdings) plc

      6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)

      1/8/25 4:16:27 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Financials

    Live finance-specific insights

    See more
    • /C O R R E C T I O N -- TC BioPharm/

      In the news release, TCBP Issues 25% Stock Dividend, issued 30-Dec-2024 by TC BioPharm over PR Newswire, we are advised by the company that in the fourth paragraph, both instances of "January 8" should instead read "January 7". The complete, corrected release follows: TCBP Issues 25% Stock Dividend EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend.

      12/30/24 10:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Issues 25% Stock Dividend

      EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend. Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special dividend of 0.25 American Depositary Shares ("ADSs") for every 1 ADS he

      12/30/24 10:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

      EDINBURGH, Scotland, Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting of shareholders ("GM") at 2:00 p.m. (UK time) on Monday, December 30, 2024, at The Seafield Arms Hotel, 17-19 Seafield St, Cullen, Buckie AB56 4SH, Scotland, United Kingdom.

      12/18/24 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

      SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

      11/14/24 4:41:42 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc (Amendment)

      SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

      2/14/24 2:34:04 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc (Amendment)

      SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

      1/29/24 9:16:48 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Leadership Updates

    Live Leadership Updates

    See more
    • TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer

      EDINBURGH, Scotland, Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the position of Chief Technology Officer. Dr. Leek resumes operational duties as CTO after stepping down as executive chairman of the board. With more than 35 years experience in cell-based research and development, Co-founder, Michael Leek, Ph.D., had previously served as TC BioPharm's Exec

      2/23/23 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TC BioPharm Announces New Chair of the Board, Arlene Morris

      EDINBURGH, Scotland, Feb. 14, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Arlene M. Morris to the position of Chair of the Board. Ms. Morris has held a seat on the TC BioPharm board as an independent director since 2022. An accomplished biotech executive and board member, with many years of experience, Ms. Morris has a proven track record of evolving businesses and en

      2/14/23 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division

      Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Bree Harlin as Chief Clinical Officer (CCO), effective immediately. Ms. Harlin brings more than twenty years of experience in research, oncology and clinical stage drug development to TC BioPharm.  Most recently she was with Loxo at Lilly, where

      1/30/23 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Randall Diana Elizabeth bought $350,000 worth of Ordinary Shares [ADS] (70,000 units at $5.00)

      4 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

      1/11/23 4:29:05 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Randall Mark Edward bought $350,000 worth of Ordinary Shares [ADS] (70,000 units at $5.00) (Amendment)

      4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)

      1/11/23 4:09:21 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Randall Kenneth Edward bought $350,000 worth of Ordinary Shares [ADS] (70,000 units at $5.00) (Amendment)

      4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)

      1/11/23 3:59:36 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TCBP Announces Transition from Nasdaq to OTC Markets

      EDINBURGH, Scotland, March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March 20, 2025, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. Management is currently working on an appeal with Nasdaq.

      3/21/25 10:45:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

      The company is expected to reduce core operational burn by 55% when compared to 2024EDINBURGH, Scotland, March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more decentralized model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. 

      3/18/25 8:03:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

      FDA-approved product in a multi-billion-dollar marketRevenue generation projected in 2025EDINBURGH, Scotland, March 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company focused on commercializing novel therapies for decreasing intraocular pressure in patients with glaucoma and ocular hypertension.

      3/5/25 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care